Compare Abeona Therapeutics Inc (ABEO) vs C.H. Robinson Worldwide, Inc. (CHRW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs C.H. Robinson Worldwide, Inc. — how do they compare? Abeona Therapeutics Inc trades at $6.75 (market cap $373.32M), while C.H. Robinson Worldwide, Inc. trades at $189.82 (market cap $22.49B). The key difference: C.H. Robinson Worldwide, Inc. is far larger — about 60.2× Abeona Therapeutics Inc's market cap, and C.H. Robinson Worldwide, Inc. pays a 1.32% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CHRW | |
|---|---|---|
Market Cap | $373.32M | $22.49B |
Sector | Health | Industrials |
52-Week High | $7.23 | $200.59 |
52-Week Low | $4.17 | $96.82 |
Enterprise Value | $228.22M | $23.98B |
Dividend Yield | — | 1.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
CH Robinson Worldwide (CHRW) trades at $190.95, up 0.58% with a bullish technical outlook. The stock shows strong profitability with ROE of 34.84% and has beaten earnings estimates for three consecutive quarters. Recent acquisitions like DeSpir Logistics and AI technology launches position the company for growth in logistics efficiency. Valuation metrics appear elevated with P/E of 38.18, though revenue has declined from 2022 peaks to $16.23B in 2025.
The outlook remains positive with analyst consensus target of $198.83 representing 4% upside. Key opportunities include AI-driven supply chain optimization and industry consolidation benefits, while risks involve freight market volatility and competitive pressures. Cash flow generation remains healthy with $915M operating cash flow in 2025 supporting dividend payments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About C.H. Robinson Worldwide, Inc.
C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (57% of 2021 net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm also operates a large air and ocean forwarding division (34%), which has grown organically and via tuck-in acquisitions. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.
Read more on CHRW →
